More than 30 presentations reinforce the role of Dupixent in targeting IL-4 and IL-13, key drivers of the type 2 inflammation underlying atopic dermatitis in children, adolescents and adults
Results provide insight into the clinical and real-world experience of Dupixent on disease measures including itch, disease severity, sleep, and anxiety
Dupixent presentations include longest duration of data for any biologic medicine in adults with moderate-to-severe atopic dermatitis, with results up to 3.5 years
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that new Dupixent (dupilumab) analyses in patients as young as six years old with moderate-to-severe atopic dermatitis will be presented at the 14th World Congress of Pediatric Dermatology Annual Congress (WCPD) from September 22-25 and the 30th European Academy of Dermatology and Venereology Congress (EADV) from September 29-October 2.
'Moderate-to-severe atopic dermatitis can severely affect people from infancy into adulthood, often causing a lifetime of debilitating symptoms like intense itch, skin lesions covering much of the body, impaired mental well-being and an increased risk of skin infections,' said Bola Akinlade, M.D., Vice President, Clinical Sciences, Immunology and Inflammation at Regeneron. 'Our broad portfolio of data at WCPD and EADV helps provide much-needed insight into the long-term effects of the disease, as well as the impact of Dupixent on physical symptoms and quality of life measures through different stages of life.'
Notable Dupixent presentations include long-term efficacy and safety data showing the impact of Dupixent on signs and symptoms of moderate-to-severe atopic dermatitis in children, adolescents and adults. More than 30 presentations highlight Dupixent results on skin lesions, itch and skin infections, as well as sleep and health-related quality of life, for patients and their families, such as in adults with a history of mental health disorders and in children with anxiety and depression. Real-world evidence will also be presented from observational registries and claims databases across multiple geographies.
Disease burden data to be presented at EADV include results from the Atopic Dermatitis Global Adolescent and Pediatric survey on how patients, caregivers and physicians view the full impact of moderate-to-severe atopic dermatitis, based on findings from more than 3,900 people across 13 countries. Data will also be shared from the Quality of Care in AD Initiative, which documents best practices from 32 atopic dermatitis centers across the world, focused on the value of patient education and communication.
Data to be presented at WCPD 2021
Clinical Efficacy and Safety of Dupixent in Atopic Dermatitis
Oral presentation (September 24, 3:40-3:50 pm BST):
#SP42 Long-Term Efficacy and Safety Data for Dupilumab in a Phase 3, Open-Label Extension Trial (LIBERTY AD PED-OLE) in Patients Aged 6 to < 12 Years With Uncontrolled, Moderate-to-Severe Atopic Dermatitis (AD), Michael Cork
Poster #P22: Efficacy and Safety of Dupilumab for up to 1 Year in a Phase 3 Open-Label Extension (OLE) Trial (LIBERTY AD PED-OLE) in Adolescents With Uncontrolled, Moderate-to-Severe Atopic Dermatitis (AD), Andrew Blauvelt
Poster #P23: 52-Week Laboratory Safety Findings From an Open-Label Extension (OLE) Study of Dupilumab in Adolescent Patients With Atopic Dermatitis (LIBERTY AD PED-OLE), Michael Cork
Poster #P33: Dupilumab Improved Itch in Children Aged 6-11 Years With Severe Atopic Dermatitis: Analysis From the LIBERTY AD PEDS Trial, Gil Yosipovitch
Poster #P35: IGAxBSA: An Alternative to EASI in Assessing Disease Severity and Response in Pediatric Patients With Moderate-to-Severe Atopic Dermatitis, Amy Paller
Poster #P36: Dupilumab Induces Rapid and Sustained Improvement in Clinical Signs in Children With Severe Atopic Dermatitis, Amy Paller
Poster #P38: Dupilumab Significantly Improves All POEM Components in Children Aged 6 to